Armistice Capital, LLC disclosed a 9.99% beneficial ownership stake in IceCure Medical in a Schedule 13G filing on August 14, 2026. The investment firm now holds 300,332 ordinary shares with shared voting and dispositive power.
This institutional investment follows IceCure’s August 12 financial report, which announced a 45% year-over-year revenue increase for the first half of 2026. The company also recently secured new peer-reviewed publications supporting its cryoablation technology for breast cancer treatment.